Qualigen Therapeutics, Inc.
QLGN
$3.11
$0.103.32%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -83.64% | 107.00% | |||
| Gross Profit | 83.64% | -107.00% | |||
| SG&A Expenses | 16.09% | -6.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.13% | 22.44% | |||
| Operating Income | 27.13% | -22.44% | |||
| Income Before Tax | -21.55% | 27.24% | |||
| Income Tax Expenses | -83.33% | -166.67% | |||
| Earnings from Continuing Operations | -21.50% | 27.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.80% | 22.44% | |||
| EBIT | 27.13% | -22.44% | |||
| EBITDA | 27.14% | -22.46% | |||
| EPS Basic | 54.70% | 41.11% | |||
| Normalized Basic EPS | 44.67% | 23.14% | |||
| EPS Diluted | 54.70% | 41.11% | |||
| Normalized Diluted EPS | 44.67% | 23.14% | |||
| Average Basic Shares Outstanding | 155.03% | 27.92% | |||
| Average Diluted Shares Outstanding | 155.03% | 27.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
